Supernus Pharmaceuticals Appoints James Kelly as Chief Financial Officer

Greg Patrick to Retire as Main Fiscal Officer ROCKVILLE, Md., Oct. 05, 2020 (World NEWSWIRE)…

Greg Patrick to Retire as Main Fiscal Officer

ROCKVILLE, Md., Oct. 05, 2020 (World NEWSWIRE) — Supernus Prescribed drugs, Inc. (Nasdaq: SUPN), a pharmaceutical enterprise focused on acquiring and commercializing solutions for the cure of central anxious process (CNS) health conditions, these days declared the appointment of James Kelly as Chief Fiscal Officer, effective October 12, 2020. Mr. Kelly delivers to Supernus about 25 many years of biopharmaceutical marketplace experience, together with most recently as Main Money Officer and Treasurer of Vanda Prescribed drugs Inc. Mr. Kelly will be accountable for acquiring and main Supernus’ financial operations and method to efficiently guidance the Company’s development. Greg Patrick, who will be retiring from his role as Supernus’ Main Economical Officer, will remain an advisor to the Corporation to help with the changeover.

“Jim provides to Supernus a established monitor record of financial leadership working experience, which includes almost 10 yrs as chief financial officer of a community biopharmaceutical corporation,” reported Jack Khattar, President and CEO of Supernus. “Jim’s fiscal and business enterprise experience will be invaluable as we progress our enterprise forward. We are thrilled to have him join us at such an fascinating time.”

Mr. Kelly is a highly experienced biopharmaceutical government who brings solid abilities and working experience in the financial stewardship of publicly-traded firms, advancement and commercialization of pharmaceutical products and solutions, execution and management of strategic transactions and collaborations and considerable money markets working experience funding progress providers. Most just lately, Mr. Kelly was the Chief Monetary Officer of Vanda Prescription drugs, a public biopharmaceutical enterprise from 2010 to 2020. Prior to signing up for Vanda, Mr. Kelly was Vice President, Controller at Medimmune, a biotechnology subsidiary of the AstraZeneca Team, the place he managed international fiscal accounting and reporting. He joined MedImmune as Director of Product sales and Promoting Finance in 2006. Prior to MedImmune and commencing in 2000, Mr. Kelly was at Biogen serving in investigation & advancement finance roles of rising accountability, most a short while ago as the Director of Scheduling and Operations. From 1997 to 2000, Mr. Kelly was a member of the company finance crew at Aetna Inc. responsible for mergers and acquisitions and treasury management. He began his lifetime sciences job in 1991 with Janssen Pharmaceutica, a division of Johnson & Johnson. Mr. Kelly holds an M.B.A. in Finance from Cornell University and a B.S. in Small business Administration from the College of Vermont. In addition, he is a Chartered Economic Analyst.

“On behalf of Supernus’ workforce and Board of Administrators, I want to thank Greg for his yrs of dedicated leadership, money willpower, a lot of contributions to Supernus and his determination to a smooth transition of the financial reins of the Firm,” added Mr. Khattar. “Since joining Supernus as Chief Financial Officer in 2011, Greg has constructed a potent team, set up the Organization on a reliable financial foundation, and guided the Enterprise through two productive merchandise launches, various financings and a significant acquisition.”

About Supernus Pharmaceuticals, Inc.Supernus Pharmaceuticals, Inc. is a pharmaceutical company concentrated on developing and commercializing products and solutions for the therapy of central nervous technique (CNS) illnesses. The Enterprise markets Trokendi XR® (prolonged-release topiramate) for the prophylaxis of migraine and the treatment of epilepsy Oxtellar XR® (extended-launch oxcarbazepine) for the treatment of epilepsy APOKYN® (apomorphine hydrochloride injection) for the acute remedy of hypomobility in highly developed Parkinson’s disorder (PD) MYOBLOC® (rimabotulinumtoxinB) for the remedy of cervical dystonia and cure of long-term sialorrhea in adults and XADAGO® (safinamide) as an adjunctive treatment method to levodopa/carbidopa in PD clients with hypomobility. The Enterprise is also producing several product candidates to handle significant market alternatives in the CNS market, together with SPN-812 for the treatment method of ADHD SPN-830 for hypomobility in PD SPN-820 for remedy-resistant despair and SPN-817 for the remedy of epilepsy.

See total Prescribing Information and facts for our solutions here: Trokendi XR, Oxtellar XR, APOKYN, MYOBLOC, and XADAGO.

All logos are the house of their respective house owners.

Ahead-Hunting Statements:This push release features ahead-on the lookout statements in the that means of the Personal Securities Litigation Reform Act of 1995. These statements do not convey historical information and facts, but relate to predicted or probable long term activities that are based mostly upon management’s present anticipations. These statements are topic to hazards and uncertainties that could induce real effects to differ materially from all those expressed or implied by such statements. In addition to the factors outlined in this push launch, these kinds of threats and uncertainties involve, but are not minimal to, the Company’s capability to sustain and boost its profitability the Company’s capacity to elevate enough capital to fully put into action its corporate technique the implementation of the Company’s corporate approach the Company’s upcoming financial general performance and projected expenditures the Company’s means to raise the number of prescriptions created for every of its solutions the Company’s ability to improve its web earnings the Company’s ability to enter into foreseeable future collaborations with pharmaceutical corporations and tutorial institutions or to attain funding from govt organizations the Company’s products exploration and advancement pursuits, together with the timing and progress of the Company’s medical trials, and projected expenses the Company’s skill to receive, and the timing of any receipt of, regulatory approvals to produce and commercialize the Company’s products candidates the Company’s ability to guard its mental house and work its business devoid of infringing on the intellectual house legal rights of some others the Company’s anticipations pertaining to federal, condition and foreign regulatory needs the therapeutic rewards, performance and security of the Company’s products candidates the precision of the Company’s estimates of the dimension and properties of the marketplaces that may perhaps be addressed by its merchandise candidates the Company’s potential to maximize its production abilities for its items and product candidates the Company’s projected markets and expansion in marketplaces the Company’s products formulations and patient requires and opportunity funding resources the Company’s staffing requires and other threat variables set forth from time to time in the Company’s filings with the Securities and Exchange Commission manufactured pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended. The Corporation undertakes no obligation to update the details in this push launch to mirror activities or circumstances right after the date hereof or to mirror the occurrence of predicted or unanticipated functions.

CONTACTS:Jack A. Khattar, President and CEOGregory S. Patrick, Senior Vice President and CFOSupernus Pharmaceuticals, Inc.Tel: (301) 838-2591

or

Investor Get in touch with:Peter VozzoWestwicke, an ICR FirmWorkplace: (443) 213-0505Mobile: (443) 377-4767Email: [email protected]

Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc.